Table 4.
The summary of studies of HAG regimen for AML, high-risk MDS and MDS/AML
| Reference | Patients type | No. | CR, % |
|---|---|---|---|
|
Wei 2006 [[76]] |
Refractory or relapsed AML |
20 |
70.0 |
|
Zhang 2008 [[77]] |
Refractory or relapsed AML |
36 |
50.0 |
|
Ji 2010 [[78]] |
Refractory or relapsed AML |
37 |
46.0 |
|
Gu 2011 [[79]] |
Refractory or relapsed AML |
67 |
52.2 |
|
Liu 2006 [[80]] |
Elderly AML |
31 |
58.1 |
|
Shu 2007 [[84]] |
MDS-RAEB |
28 |
53.6 |
|
Su 2008 [[85]] |
High-risk MDS or MDS/AML |
33 |
46.7 |
|
Wu 2009 [[86]] |
High-risk MDS or MDS/AML |
32 |
46.9 |
| Wu 2011 [[87]] | Elderly high-risk MDS or MDS/AML | 33 | 57.6 |
HAG homoharringtonine + arabinoside + G-CSF, CR complete remission, AML acute myeloid leukemia, MDS myelodysplastic syndrome.
MDS/AML MDS evolving to AML.